RxDoctor Payments Data

Stephanie Stone

Physician Assistant · Newport Beach, CANPI 1548579972

Payments from drug & device makers

$4,075in general payments, 2019–2025

Across 121 payments — averaging $33.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • Exact Sciences$304
  • Amgen$286
  • AbbVie$283
  • AstraZeneca$234
  • Lilly USA, LLC$229
  • plus $1K from 21 others

What the payments were for

  • Consulting fees$80020%
  • Travel & lodging$3338%
  • Food & beverage$2,94272%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,075 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$34,369
Medicare patients
201
Services billed
369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SynthroidLevothyroxine Sodium14$1,002
Gabapentin36$472
Bupropion XlBupropion Hcl16$470
Levothyroxine Sodium48$469
Losartan Potassium50$446
Metoprolol Succinate26$424
Atorvastatin Calcium51$352
Rosuvastatin Calcium25$338
Omeprazole11$321
Albuterol Sulfate HfaAlbuterol Sulfate15$301
Lisinopril36$283
Duloxetine Hcl13$283
Tamsulosin Hcl15$261
Amlodipine Besylate62$249
Famotidine21$173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$283$1,00214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →